Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer

Anticancer Res. May-Jun 2003;23(3C):2945-50.


Background: Urokinase-type plasminogen activator (u-PA) has been reported to overexpress in several types of human cancers and correlate with cancer progression. The present study was performed to evaluate the significance of expression of u-PA on the progression of prostate cancer.

Materials and methods: Expression of u-PA protein was investigated immunohistochemically on paraffin-embedded section from 61 patients with untreated prostate cancer. The correlation between the u-PA expression and clinical outcome was examined.

Results: u-PA was expressed in the cytoplasm of glandular cells of 56% patients. Higher expression of u-PA protein was positively correlated with bone metastasis (p = 0.011). The cause-specific survival rate was significantly lower in u-PA-positive patients than that in u-PA-negative patients (p = 0.0012). In those with bone metastasis, patients with u-PA expression had worse cause-specific survival than those without u-PA expression (p = 0.030).

Conclusion: Increased expression of u-PA is a feature of bone metastasis in patients with prostate cancer. u-PA expression is a prognostic factor in patients with prostate cancer.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal
  • Biopsy
  • Bone Neoplasms / blood
  • Bone Neoplasms / enzymology
  • Bone Neoplasms / secondary
  • Disease Progression
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Paraffin Embedding
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / enzymology*
  • Prostatic Neoplasms / pathology
  • Urokinase-Type Plasminogen Activator / biosynthesis*


  • Antibodies, Monoclonal
  • Urokinase-Type Plasminogen Activator
  • Prostate-Specific Antigen